Cybin Inc. has announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. patent 11,724,985 to a deuterated psilocybin analogue in the company’s CYB003 investigational drug programme.
The patent, which is expected to provide exclusivity until 2041, includes composition of matter claims to deuterated tryptamines in support of Cybin’s clinical-stage programmes.
These include CYB003, a proprietary deuterated psilocybin analogue, and CYB004, a proprietary deuterated DMT, in addition to other of the company’s pre-clinical programmes and claims directed towards methods of treating major depressive disorder (MDD) and treatment-resistant depression.
CEO of Cybin, Doug Drysdale, commented: “We are very pleased to announce this composition of matter patent supporting our clinical-stage CYB003 programme, which strengthens our growing intellectual property portfolio and leadership position as a developer of differentiated therapeutics for mental health, especially as we work diligently to advance our clinical trials towards topline data readouts later this year.
“With this patent granted, we move forward with conviction in our mission of bringing novel, improved treatment options to people suffering from anxiety and depression.”
CYB003 is an investigational proprietary deuterated psilocybin analogue program being developed for the potential treatment of MDD. As a deuterated molecule, CYB003 is designed to potentially achieve an optimized therapeutic profile, including rapid onset of effect, short treatment duration, and efficacy at low doses. CYB003 is currently being evaluated in a Phase 2 clinical trial in participants with moderate to severe MDD.
CYB004 is an investigational deuterated DMT program in development for the potential treatment for Generalized Anxiety Disorder (“GAD”). CYB004 dosing underway is Part C of the Company’s three-part Phase 1 CYB004-E clinical trial evaluating intravenous (“IV”) DMT and CYB004 in healthy volunteers.
Cybin has stated that it expects to report topline Phase 2 efficacy data for CYB003 in MDD and topline Phase 1 data from the CYB004-E study in Q3/Q4 2023.
